Analysts expect that ChemoCentryx Inc (NASDAQ:CCXI) will announce $10.08 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for ChemoCentryx’s earnings. The highest sales estimate is $15.00 million and the lowest is $8.00 million. ChemoCentryx reported sales of $15.02 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 32.9%. The company is expected to report its next earnings results on Thursday, August 8th.
According to Zacks, analysts expect that ChemoCentryx will report full-year sales of $38.99 million for the current fiscal year, with estimates ranging from $32.33 million to $53.33 million. For the next year, analysts anticipate that the company will post sales of $49.07 million, with estimates ranging from $31.48 million to $72.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. The company had revenue of $8.33 million during the quarter, compared to the consensus estimate of $11.37 million. ChemoCentryx had a negative return on equity of 111.15% and a negative net margin of 97.22%.
CCXI has been the topic of several research analyst reports. Raymond James restated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, June 6th. HC Wainwright boosted their price objective on shares of Applied Genetic Technologies from $5.75 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. BidaskClub cut shares of Virtu Financial from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 12th. ValuEngine cut shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Finally, Zacks Investment Research raised shares of HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research note on Friday, May 17th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $17.71.
NASDAQ CCXI traded down $0.18 during trading hours on Thursday, reaching $8.68. The company’s stock had a trading volume of 9,023 shares, compared to its average volume of 499,798. The company has a 50-day moving average of $9.57. The company has a market cap of $516.63 million, a PE ratio of -11.55 and a beta of 1.11. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.43 and a current ratio of 3.43. ChemoCentryx has a 52 week low of $8.06 and a 52 week high of $14.98.
In related news, Director Geoffrey M. Parker sold 12,815 shares of the business’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $12.00, for a total transaction of $153,780.00. Following the transaction, the director now owns 85,014 shares in the company, valued at approximately $1,020,168. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Rajinder Singh sold 33,000 shares of the business’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $12.96, for a total transaction of $427,680.00. Following the sale, the senior vice president now owns 43,614 shares of the company’s stock, valued at approximately $565,237.44. The disclosure for this sale can be found here. Insiders own 12.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of CCXI. Rhumbline Advisers lifted its position in ChemoCentryx by 44.9% during the fourth quarter. Rhumbline Advisers now owns 30,596 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 9,479 shares in the last quarter. SG Americas Securities LLC acquired a new position in ChemoCentryx during the 4th quarter worth $196,000. Bank of New York Mellon Corp grew its stake in ChemoCentryx by 10.2% during the 4th quarter. Bank of New York Mellon Corp now owns 139,805 shares of the biopharmaceutical company’s stock worth $1,525,000 after purchasing an additional 12,957 shares in the last quarter. Raymond James & Associates acquired a new position in shares of ChemoCentryx during the 4th quarter worth about $133,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of ChemoCentryx by 15.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 632,061 shares of the biopharmaceutical company’s stock worth $6,896,000 after acquiring an additional 84,290 shares in the last quarter. Hedge funds and other institutional investors own 58.14% of the company’s stock.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Further Reading: How Do Investors Open a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.